小剂量吉西他滨联合顺铂时序用药对晚期肺腺癌的临床研究

目的 探讨临床中晚期肺腺癌患者应用小剂量吉西他滨与顺铂时序用药治疗效果.方法 选取我院2009年1月至2009年12月80例晚期肺腺癌患者为研究对象,将其按照随机数字法分为研究组和对照组,研究组给予小剂量吉西他滨与顺铂时序用药治疗,对照组给予小剂量吉西他滨与顺铂常规用药治疗,观察两组的治疗效果.结果 研究组治疗有效率为65.0％,对照组治疗有效率为42.5％,研究组治疗有效率明显的高于对照组,差异有统计学意义（P＜0.05）.研究组骨髓抑制、血小板减少和粒细胞减少以及周围神经损害与恶心、呕吐发生率均明显的低于对照组,差异有统计学有意义（P＜0.05）.研究组和对照组1年后的生存率分别为72.5％、70.0％,两组的数据比较差异无统计学意义（P＞0.05）;研究组和对照组3年后生存率分别为52.5％、27.5％,两组的数据比较差异有统计学意义（P＜0.05）.结论 临床中对于晚期肺腺癌患者应用小剂量吉西他滨与顺铂联合治疗采取时序用药治疗效果显著,毒副反应少,值得临床中应用与推广.

Clinical study on small doses of gemcitabine plus capsulation in treatment of advanced lung adenocarcinoma sequence

Objective To evaluate the clinical application of advanced lung cancer patients with small doses of gemcitabine and capsulation timing of drug treatment.Methods In our hospital from January 2009 to December 2009,80 patients with advanced lung cancer patients were selected for the study,they were randomly divided into study group and control group,study group was given a small dose of gemcitabine and capsulation timing of medication treatment,the control group was given a small dose of gemcitabine and capsulation with conventional drug treatment,the treatment effects were observed in both groups.Results The response rate was 65.0％ in the treatment group,higher than that of the control group （42.5％）,showing statistical significant difference （P ＜ 0.05）.Study group＇ s myelosuppression,thrombocytopenia and neutrogena and peripheral nerve damage and nausea and vomiting were significantly lower than those of the control group,with statistical significant difference （P ＜ 0.05）.l-year survival rates of study group and the control group were 72.5％,70.0％ respectively,showing no significant difference （P ＞ 0.05）; three-year survival rates of study group and the control group were 52.5％ and 27.5％ respectively,showing statistical significant difference （P ＜ 0.05）.Conclusion For clinical application of advanced lung cancer patients a small dose of gemcitabine and capsulation combination therapy taking medication timing has significant treatment effect,with less adverse reaction,which is worthy of clinical application and promotion.